KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for AbbVie (ABBV) over the last 14 years, with Q3 2025 value amounting to $381.0 million.

  • AbbVie's Capital Expenditures rose 5301.2% to $381.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year increase of 3243.24%. This contributed to the annual value of $974.0 million for FY2024, which is 2535.39% up from last year.
  • Latest data reveals that AbbVie reported Capital Expenditures of $381.0 million as of Q3 2025, which was up 5301.2% from $269.0 million recorded in Q2 2025.
  • In the past 5 years, AbbVie's Capital Expenditures ranged from a high of $381.0 million in Q3 2025 and a low of $143.0 million during Q2 2022
  • Over the past 5 years, AbbVie's median Capital Expenditures value was $205.0 million (recorded in 2023), while the average stood at $216.7 million.
  • In the last 5 years, AbbVie's Capital Expenditures plummeted by 3297.49% in 2021 and then skyrocketed by 5301.2% in 2025.
  • Over the past 5 years, AbbVie's Capital Expenditures (Quarter) stood at $187.0 million in 2021, then grew by 13.9% to $213.0 million in 2022, then dropped by 3.76% to $205.0 million in 2023, then soared by 41.95% to $291.0 million in 2024, then skyrocketed by 30.93% to $381.0 million in 2025.
  • Its Capital Expenditures was $381.0 million in Q3 2025, compared to $269.0 million in Q2 2025 and $235.0 million in Q1 2025.